Bolt Biotherapeutics Q2 EPS $(0.56) Misses $(0.48) Estimate, Sales $1.27M Beat $891.50K Estimate
Portfolio Pulse from Benzinga Newsdesk
Bolt Biotherapeutics (NASDAQ:BOLT) reported Q2 EPS of $(0.56), missing the $(0.48) estimate by 16.67%. Sales were $1.27M, beating the $891.50K estimate by 43.02%.
August 13, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bolt Biotherapeutics reported a Q2 EPS of $(0.56), missing the $(0.48) estimate by 16.67%. However, sales of $1.27M beat the $891.50K estimate by 43.02%.
The mixed earnings report, with a significant EPS miss but a strong sales beat, creates a neutral short-term outlook for BOLT. Investors may weigh the negative EPS against the positive sales performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100